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Abstract
Background: The impact on patients suffering from chronic hand eczema (CHE) is enormous, as no licensed systemic 
treatment option with proven efficacy for CHE is available. Alitretinoin is a novel agent which showed high clinical 
efficacy in patients with severe, refractory CHE. We assessed the cost-effectiveness of alitretinoin for CHE patient 
treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of 
disease in Switzerland.
 Methods : A long-term Markov cohort simulation model was used to estimate direct medical costs (€) and clinical 
effectiveness (quality adjusted life years, QALYs) of treating severe CHE patients with alitretinoin. Comparison was 
against the standard treatment of supportive care (optimised emollient therapy). Information on response rates were 
derived from a randomized controlled clinical trial. Costs were considered from the perspective of the Swiss health 
system. Swiss epidemiological data was derived from official Swiss Statistic institutions.
 Results : Annual costs of alitretinoin treatment accounted for €2'212. After a time horizon of 22.4 years, average 
remaining long-term costs accounted for €42'208 or €38'795 in the alitretinoin and the standard treatment arm, 
respectively. Compared with the standard therapy, the addition of alitretinoin yielded an average gain of 0.230 QALYs at 
the end of the simulation. Accordingly, the incremental cost-effectiveness ratio resulted in €14'816/QALY gained. 
These results were robust to changes in key model assumptions.
 Conclusion : The therapy for CHE patients is currently insufficient. In our long-term model we identified the treatment 
with alitretinoin as a cost-effective alternative for the therapy of CHE patients in Switzerland.
Background
Hand eczema is a widespread dermatological condition
associated with a chronic course and poor healing rates
[1]. Particularly in severe patients, the response to the
treatment is commonly very bad. Despite the currently
available therapies, the illness leads frequently to a
chronic course [1,2]. It is well known that patient's quality
of life is affected negatively by restricted function of the
hands, severe psychological strain and also economical
implications [3-5].
The prevalence of patients with hand eczema is esti-
mated at 7% to 12% in the general population [5,6]. How-
ever, the fraction of severe chronic hand eczema (CHE)
among hand eczema patients is assumed to be 5-7%,
whereas 2-4% are estimated to be refractory to topical
steroids[7]. Given that epidemiological data on CHE is
scarce, it is difficult to assess an exact figure of the fre-
quency of work-related CHE [6,8-10].
Mild eczema patients are mostly treated with emol-
lients and topical corticosteroids. On the other hand, only
limited treatment agents for severe chronic hand eczema
refractory to the standard therapy with topical steroids
are available including off-label used agents. Despite the
use of these treatments, the efficacy of these treatments
remains questionable. Hence, there is a strong need for a
novel CHE therapy.
In 2008, alitretinoin, a 9-cis retinoic acid was firstly reg-
istered in Germany for use in patients with severe CHE
refractory to potent topical corticosteroids [11]. The
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Page 2 of 9agent was shown to be highly effective in several clinical
trials including the BACH-trial a randomized, double
blind, placebo-controlled study in patients with CHE.
The anti-inflammatory and immunomodulatory proper-
ties of alitretinoin induce high response rates with a
favourable safety-profile over a long-term management
of the treatment [12-14]. Since 2009, alitretinoin (Toc-
tino®, Basilea Pharmaceutica International AG, Basel) has
been approved for severe, refractory CHE in Switzerland.
Economic evaluations are essential key implications for
health policy and decision makers[15]. Nevertheless, due
to the lack of data on costs associated with CHE, only few
international studies have measured the economic bur-
den of disease. Some studies exist which reported possi-
ble change or even lost of employment in patients with
work-related hand eczema [16,17]. The annual costs for
work-related CHE was estimated at €9'000[5]. Hence, the
health economic impact of disease may be considerable,
but data are urgently required to enlighten this issue.
This health economic study aimed to assess the cost-
effectiveness of oral alitretinoin in patients with severe
CHE refractory to potent topical corticosteroid. The per-
spective was from the Swiss health care system. In addi-




A Markov decision model was developed to estimate the
cost and effectiveness of alitretinoin in patients with
severe chronic hand eczema (CHE). The model was built
using Microsoft Excel (MME Europe, Milano, Italy). Two
strategies were studied: treatment with oral alitretinoin
or supportive care (optimised emollient therapy). The
clinical data and the treatment protocol stem from two
double-blind, randomised, placebo-controlled clinical
studies (BACH) described by Ruzicka et al [12-14] and a
Swiss dermatology opinion leader (Dr. A. Blank, Zurich,
Switzerland). A hypothetical cohort of 1'000 patients was
simulated with the same endpoints, treatments used,
therapy duration, entry criteria and demographic charac-
teristics as documented in these trials [12-14]. Possible
disease stages were clear/almost clear, mild/moderate
non responders and severe non responders. The time
frame was 22.4 years. Costs and clinical benefits were
both discounted with 3.5%.
Average patient profile
Data from patients aged 18 to 75 years of age with severe
CHE non-responding to standard therapy were included
in the model. The exact patient profile was described in
an earlier publication by Ruzicka et al [12]. The clinical
study was registered with the U.S. National Institutes of
Health (NCT00124475). Health status was determined
according to the PGA criteria of clear/almost clear, mild/
moderate and severe non responders [12]. A relapse for
responding patients was defined as 'modified Total
Lesion Symptom Score' (mTLSS) ≥75% of the original
baseline value.
Treatment pathways
The schematic model is presented in Figure 1. The two
initial treatment strategies were the following: the alit-
retinoin group was treated with 30 mg once daily and the
control group (supportive care) received optimised emol-
lient care. Resource utilisation for both groups is
described in Table 1. Treatment duration was 12 to 24
weeks per cycle, depending on response.
Transition probabilities
Transition probabilities were derived from information
on response rates published by Ruzicka [12,13]. Response
rates were assessed using the investigator's assessment
(PGA scale).
Patients who responded (clear/almost clear) during the
treatment cycle discontinued the therapy after 12 weeks
at the earliest. Patients who remained in the severe state
after 12 weeks stopped the treatment and entered con-
ventional local treatment for severe non-responders.
Non-responding or mild to moderate responding patients
(after 12 weeks) were subject to receiving the therapy up
to 24 weeks. Only patients responding (clear/almost
clear) after the end of the first treatment cycle were eligi-
ble to re-enter further treatment cycles after relapse. In
the period between treatment and relapse, these patients
received maintenance therapy. The remaining patients
(mild to moderate partial responders and severe non-
responders) were treated with conventional local treat-
ment for severe non-responders (Figure 1).
The average duration of treatment for responding
patients receiving alitretinoin or supportive care was
15.43 weeks or 18.12 weeks for the first cycle and 14.77
weeks or 17.66 weeks for the re-treatment phase, respec-
tively[14]. Time to relapse was assumed to be 24 weeks
for both groups [13]. The alitretinoin and supportive care
model was terminated after 29 and 27 re-treatment
cycles, respectively. The total life span covered by the
model was 22.4 years. Model outputs included costs and
quality adjusted life years (QALYs) associated with each
treatment strategy.
Data source
Treatment usage was taken from the study protocol and
reproduced by Swiss standards [12,18]. All resource esti-
mations were discussed with a Swiss dermatologist and
considered to be realistic and appropriate.
The relevant cost data, including alitretinoin, were
derived from public prices as reported for the products
by the Swiss pharmaceutical compendium [19]. Further-
more, the Tarmed (the official Swiss Tariff code) gave
insights into the costs of medical services, diagnostics
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Switzerland, provided laboratory testing information. All
tax points were converted into Euro (1TP = CHF0.92 =
€0.613, January 2010).
Swiss epidemiology of CHE
The Central Office for Statistics in Accident Insurance
(SSUV) from the Statistics institutions in Switzerland col-
lects data on recognised occupational diseases and acci-
dents since 1997 [21,22]. Swiss incidence rates and
general costs of patients suffering from CHE were
assessed from this basis.
Resource utilization and cost input for both treatment arms
Resource utilization included the amount of used medi-
cations per cycle, concomitant topical emollients, and
rescue topical dermatological medication as well as pso-
ralen and ultraviolet A radiation (PUVA). All patients
were supposed to undergo a monthly dermatological
visit, until a complete response was achieved. Patients
reaching the status "clear/almost clear" were assumed to
cut in half the number of dermatologist visits during the
time period covered by the model. This assumption is in
concordance with daily practice, where clear patients do
not require visiting their dermatologist as frequently as
patients in a severe state. All patients were given an emol-
lient cream for daily usage.
Basis costs of alitretinoin group
Costs of basis treatment with alitretinoin included emol-
lients without an active agent and one consultation
monthly as shown in Table 1. The use of emollients was
supposed to drop by 25% when "clear/almost clear" status
reached. Due to the dose dependent effect of alitretinoin,
patients received one 30 mg capsule daily [12,13]. All
patients were treated until response was achieved. Labo-
ratory tests were established to control and analyse trig-
lycerides and cholesterols (low-density lipoprotein (LDL),
high-density lipoprotein (HDL)). Women of childbearing
age received after pregnancy tests oral contraceptives
(0.15 mg Levonorgestrel, 30 μg Ethinylestradiol) before,
during and after the treatment with the 9-cis retinoic
acid.
Table 1: Resource utilisation
Cost item Costs per month (€) Dosage per month Ref.
Basis costs for alitretinoin group
Alitretinoin 30 mg capsules 28 × €17.50 = € 490 28 × 30 mg (one capsule per day) [19]
Emollients € 25 200gr Official price in Swiss pharmacies
Pregnancy testing + oral 
contraceptives
€ 19 1 test, 21 tab [19]
Dermatologist visits € 27 1 visit [20]
Lipid monitoring tests# € 11 1 test [44]
Basis costs for placebo group
Emollients € 25 200gr Official price in Swiss pharmacies
Dermatologist visits € 27 1 visit [20]
Following costs for non-responders 
(alitretinoin or supportive care): 
Conventional local therapy for severe 
non-responders
Emollients € 25 200gr Official price in Swiss pharmacies
Dermatologist visits € 27 1 visit [20]
PUVA/311 nm (Topical/oral) € 121 20 cycles per 10 weeks in 6 months 
period (3,33 cycles per month)
[20]
Topical steroids Class I-III € 30 60 gr [19]
Topical steroids Class IV € 17 60 gr [19]
Topical steroids total* € 20 60 gr [19]
#LDL, HDL, Triglycerides.
*Assumes 25% of the patients treated with Class I-III and 75% with Class IV topical steroids
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Supportive care treatment for patients suffering from
CHE composed basis emollients without active agents
and one monthly dermatologist visit as described in Table
1.
Costs of following treatment
Responders received maintenance therapy for clear or
almost clear patients, including emollients and dermatol-
ogist visits, as described above. Mild responders or severe
non-responders were treated with conventional local
care. This group obtained, besides the basic therapeutic
interventions (emollients, consultations) psoralen and
ultraviolet A radiation (PUVA) as well as applied topical
steroids. The model assumed that twenty PUVA sessions
were used during ten weeks in a six month period (2 ses-
sions per week). Hence, the yearly average of PUVA ther-
apy would sum up to 40 sessions. Per PUVA cycle 40 mg
8-methoxypsoralen were given (assumed body weight of
66-80 kilogram). PUVA baths were not taken into consid-
eration as their usage is uncommon in Switzerland. Pred-
nicarbonate (0.25%) and mometasone-17-furoate (0.1%)
have moderate anti-inflammatory effects and were used
as topical steroid class III. Clobetasol-proprionate
(0.05%) was used for strong or very strong anti-inflamma-
tory virulence (class IV) (Table 1).
Utilities
CHE may impair the qualities of life of the patient itself
and of the patients' family. According to the National
Institute for Health and Clinical Excellence (NICE) guid-
ance document on adalimumab in psoriasis, severe psori-
asis is defined as "a total Psoriasis Area Severity Index
(PASI) of 10 or more and a Dermatology Life Quality
Index (DLQI) of more than 10" [23]. Hence, CHE patients
with a PGA status of severe, having a DLQI score greater
than 10, can be compared to severe psoriasis patients in
regard to the impact of the disease on their life-quality
[24].
A 'mapping' exercise was carried out to estimate the
association between psoriasis-related quality of life
(QOL) (as measured by the DLQI) and utility (using the
EQ-5D). The DLQI values were converted to EQ-5 D util-
ity weights using the algorithm from Woolacott et al [25].
The following utility mapping formula was applied: EQ-5
D utility score = 0.956- [0.0248 × (DLQI total score)]]
[25]. The underlying data of the DLQI scores by PGA
severity was assessed from a study conducted by Free-
Figure 1 Flow of model.
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was also used in the recent NICE health economic
appraisal of alitretinoin and assumed as adequate [27].
Utility values used in the model are visible in Table 2.
Sensitivity analysis
In order to analyse the sensitivity of the model outcome,
the most relevant clinical scenarios were considered in
several univariate sensitivity analysis. The following key
input parameters were taken in account: utilities related
to all PGA states, supportive care costs, use of PUVA and
efficacy of supportive care. To identify the most relevant
input parameters, which influence the base case result,




After the first cycle, the cumulative response rate in the
alitretinoin and the supportive care group was 47.7% and
16.6%, respectively [12]. The cumulative efficacy of clear/
almost clear patients in the re-treatment cycles achieved
79.6% in the alitretinoin and 25.5% in the supportive care
fraction[18].
The monthly drug costs of CHE patients are presented
in Table 3. In the group of alitretinoin, costs summed up
to €556, whereas the expenses of the supportive care
treatment resulted in €52 per month. Patients with a
clear or almost clear status accounted for €33 and the
conventional local treatment of severe non responders
was €193 (Table 3).
During the entire modelling period, PUVA sessions per
non-responding patient in the alitretinoin and the sup-
portive care group resulted in 294.5 (according to 38.7
weeks on PUVA) and 295.9 (according to 41.7 weeks on
PUVA), respectively. The total costs of a patient treated
with alitretinoin or conventional treatment summed up
to €42'208 or €38'795, respectively. Differences in effec-
tiveness between the two therapies arose from the much
higher response rate in the alitretinoin group compared
to supportive care. Hence, patients receiving alitretinoin
yielded on average a gain of 11.21 quality adjusted life
years (QALYs). Patients in the supportive care group
resulted in a lower efficacy (10.98 QALYs). Hence, alit-
retinoin therapy was associated with incremental costs of
€3'413, accompanied with a gain of 0.23 QALYs per
patient. Accordingly, the corresponding incremental
cost-effectiveness ratio (ICER) was €14'816 per QALY
gained, when compared with the control group.
Table 4 presents other Swiss cost-effectiveness studies.
Alitretinoin treatment was cost-effective in comparison
with existing cost-effectiveness thresholds.
Sensitivity analysis
Several one-way sensitivity analyses were performed in
order to guarantee the models' insensitiveness to particu-
lar parameter variations. For the analyses, model parame-
ters were selected as described in the methods and were
tested for their impact on the base case result. The
impact of the scenario analyses (± 30% or ± 35% variation
of selected parameters) on ICER results was minor (Fig-
ure 2).
Burden of disease of CHE in Switzerland
According to the SSUV, 1147 cases of CHE patients were
reported during the period between 1997 and 2006,
whereof 91 patients were counted in the year 2006[21].
Consequently, the proportion of CHE in Switzerland
ranges up to 2 per 100'000 habitants (total working popu-
lation in 2006 (20-65 years of age): 4'319'266)[28]. These
data are limited to work related cases covered by SSUV;
hence, the incidence reported by the SSUV is underesti-
mating the total number of Swiss CHE patients.
Discussion and conclusion
Eczema of hands due to occupational activities is a com-
mon disease in industrialised countries. Treatment
options for CHE patients are ample, but the efficacy is
limited. Current existing therapies include topical or sys-
temic treatments, avoidance of the exposed irritants by
gloves, educational programmes and lifestyle changes
[7,29-31]. Local phototherapy, and off-label use of retin-
oids, calcineurin inhibitors, immune suppressants such as
systemic steroids and ciclosporin are alternative escala-
tion steps for those who do not respond adequately to
standard care including topical steroids [32].
The object of this study was to assess the economic
impact of using alitretinoin treatment for patients with
chronic hand eczema refractory to standard treatment.
Using the effectiveness data from a published clinical trial
and cost assumptions based on the Swiss health system, a
Table 2: Utility values in the model
Clear/almost clear Mild/moderate Severe Notes
DLQI Scores by PGA status 1.74 7.86 15.08 [26]
EQ-5 D Values* 0.913 0.761 0.625 [25]
*EQ-5 D utility score = 0.956 - [0.0248 × (DLQI total score)].
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retinoin versus supportive care in Swiss patients. End-
points, treatment used in the two arms, duration of
therapy and the follow up of the published multicenter
trial (BACH trial) were exactly reproduced in the Swiss
regimen [12,18].
As reported by Ruzicka et al, the effectiveness data used
in our model reached in the alitretinoin group nearly
three times higher response rates (defined as clear or
almost clear hands) than in the supportive care treated
patients [12]. During a treatment cycle, the monthly costs
of alitretinoin therapy were put at €556 whereas support-
ive care accounted for €52. At the end of the entire simu-
lation (22.4 years), the incremental cost-effectiveness
ratio yielded in €14'816 per QALY gained. The ICER
expressed robustness for all variable variations in the
one-way sensitivity analysis.
The yearly medical average cost of alitretinoin with
treatment durations of 12.9 weeks (time-to-response in
BACH study: 1.4 cycles and 165 days relapse time) would
result in €2'212 (incl. value added tax) per patient in
Switzerland. Consequently, the daily treatment cost per
year would sum up to approximately €6.06. This estimate
can be put in perspective to systemic treatment of psoria-
sis patients indicating cost ranges from $1'197 (€957) to
$27'577 (€21'866) per year [33]. The cost-effectiveness
analysis presented above determined the ICER of alit-
retinoin treatment at €14'816 per QALY gained. Using
this result on the overall Swiss situation, we would expect
to invest additional €310'583 in alitretinoin treatment per
year to acquire a further gain of 20.93 QALYs for all new
Table 3: Average costs (per month)
Costs item Patients on 
Alitretinoin 30 mg*




Dermatologist visits €27 €27 €14 €27
Alitretinoin drug cost €490 - - -
Emollients €25 €25 €19 €25
Lipid monitoring €11 - - -
Pregnancy testing and oral 
contraception°
€3 - - -
Alternative Care Non-Responders 
(PUVA + Topical Steroids)
- - - €141
Total €556 €52 €33 €193
°Female alitretinoin patients only. Assumes that 15% of female patients are in childbearing age and needing contraception.
*Including Mild/Moderate alitretinoin non-responder.
#Including Mild/Moderate placebo non responder.
¥Alitretinoin and placebo patients receiving conventional local care
Table 4: Examples of other Swiss cost-effectiveness analyses (CEA)
Study (Ref) Indication Comparison Cost- effectiveness
[45] CEA of quadrivalent HPV vaccine in girls aged 11 
years over lifetime
Cytological screening vs. 
cytological screening with 
vaccination
€17'337/QALY*
[46] CEA of eplerenone in patients with left ventricular 
dysfunction after myocardial infarction (EPHESUS 
study)
Eplerenone vs. placebo €7'558/QALY*1 to 
€15'977/QALY*1
[47] Cost-effectiveness of trastuzumab in the adjuvant 
treatment of early breast cancer
Trastuzumab vs. standard care €40'505/LYG2
€19'673/LYG3
*Currency conversion CHF1.00 = €1.5.
1depending on survival estimate.
2after 10 years.
3after 15 years.
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91 Swiss CHE patients) [21]. This translates into total
annual costs of €1'348'256 in alitretinoin treatment to
obtain one QALY in each new CHE case in Switzerland.
Given that 3'736 occupational cases of illness were
reported in Switzerland, skin diseases in general induced
by hurtful substances correspond to 20.2% of those cases
registered during 2006 [34]. Hence, 12.1% of all skin dis-
eases recorded by the Swiss Accident Insurance Agency
correspond to CHE [21]. Similar reports from the United
States estimated the proportion of hand eczema cases in
regard to working place damages at 15% [35].
Overall, there is only little evidence of the financial bur-
den of chronic hand eczema patients in the published lit-
erature [36,37]. According to the SSUV, the expansion of
the eczema on the entire hand, forearm and/or arm
summed up to €3'428'260 in the year 2006. These costs
included medical expenses, daily allowance, integrity
reimbursement, other capital payment and net present
values of the disability pension during the entire year. The
compensated working days added up to €8'827 per year
(2006) [22]. Thus, the once daily intake of alitretinoin not
only appears to have a huge clinical and quality of life
benefit, but also a pharmacoeconomic advantage by
means of reducing the direct and indirect costs discussed
above. Cost-effectiveness analyses are key factors of
whether new treatment agents are funded or not [38].
According to the National Institute for Health and Clini-
cal Excellence (NICE) the ICER for the acceptability
threshold is determined between 20'000 GPB/QALY
(€23'322/QALY) to 30'000 GPB/QALY (€34'983/
QALY)[39]. Hence, the long-term result of our simulation
model (€14'816/QALY) is in concordance with the guide-
lines of the NICE, which are generally accepted, including
in Switzerland.
This model gives a good sense of the cost-effectiveness
of alitretinoin versus supportive care. However, the analy-
ses based on the model are subject to certain limitations.
It has to be taken into account, that only direct costs and
no indirect costs were incorporated. It should be noted
Figure 2 Scenarios of sensitivity analysis.
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high direct but also with indirect costs [40]. As an exam-
ple for skin diseases, Verboom et al stated that high cost-
of-illness was particularly found outside the health-care
system, but variations across countries are substantial
[41]. Given the much higher response rate of the alitretin-
oin group compared to the supportive care group, we
could have expected lower indirect costs which would
indirectly influence the ICER. Secondly, the findings of
our work can be hardly compared with other studies as
only few controlled clinical trials have provided adequate
evidence-based data in regard to hand eczema refractory
to standard treatment [42]. At the time of modelling,
cost-effectiveness studies on the treatment of eczema are
mostly lacking in the published literature [43]. Further-
more, we assumed constant efficacy (meaning transition
probabilities) for the re-treatment cycle. The underlying
clinical principals would presumably need some modifi-
cation during the long-term treatment process. Given the
available data source, this modification was not manage-
able in our analyses. Thirdly, our model pursued a con-
servative assumption supposing the same price of the
drug over all cycles. However, over a long-term projec-
tion, the drug price of alitretinoin is likely to be amended
due to price cuts or introduction of reference prices in
some countries. Finally, the Swiss incidence numbers uti-
lised in our economic evaluation correspond to work-
related cases. Hence, the number and costs of hand
eczema patients assessed by our work are likely to be
underestimated.
The treatment of CHE patients in Switzerland is,
according to expert opinion, insufficient as only few
patients receive a clear status with the current treatment
options. Due to the chronic course of the disease, the
quality of life and social functioning often change for the
worse. However, the new treatment option with alitretin-
oin raises hope for many patients. In our long time model
we identified the therapy with alitretinoin as a cost-effec-
tive alternative for the therapy of CHE patients in Swit-
zerland. The model used in our study may be valid not
only in the Swiss setting but also in other European coun-
tries.
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